LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein

Dou, Qianru; Xu, Yang; Zhu, Yuanyuan; Hu, Yakun; Yan, Yuchen; Yan, Hongchao

doi:10.1016/j.ejphar.2019.03.002

Cited by 48 publications

(43 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, FAM83H-AS1 could ameliorate SpA-mediated inhibition on the osteogenic differentiation of human bone mesenchymal stem cells during osteomyelitis and promote nucleus pulposus cell growth in intervertebral disc degeneration [28,29]. However, many studies recently showed that FAM83H-AS1 was overexpressed in some tumors and exhibited an oncogenic role in cell proliferation and metastasis [6,10,16]. Dou's study showed that elevated FAM83H-AS1 expression was correlated with radioresistance and poor OS and was used to effectively predict lymph node metastasis in ovarian cancer [16].…”

Section: Discussionmentioning

confidence: 99%

“…However, many studies recently showed that FAM83H-AS1 was overexpressed in some tumors and exhibited an oncogenic role in cell proliferation and metastasis [6,10,16]. Dou's study showed that elevated FAM83H-AS1 expression was correlated with radioresistance and poor OS and was used to effectively predict lymph node metastasis in ovarian cancer [16]. Previous studies confirmed that the expression of HuR was positively correlated with the expression of FAM83H-AS1.…”

Section: Discussionmentioning

confidence: 99%

“…The 14 studies contained 2818 patients from three countries including China, United States and Iran. We mainly analyzed nine different types of tumors, including pancreatic ductal adenocarcinoma [13], gastric cancer [7,14,15], ovarian cancer [8,16], glioma [9], colorectal carcinoma [17,18], bladder cancer [10], hepatocellular carcinoma [6], breast cancer [19], and lung cancer [20]. The expression of FAM83H-AS1 was detected by quantitative real-time fluorescent PCR in all studies.…”

Section: Characteristics and Basic Information In Eligible Literaturementioning

confidence: 99%

See 2 more Smart Citations

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

Yang¹,

Wang²,

Zhong³

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Family with sequence similarity 83 member H antisense RNA 1 (FAM83H-AS1) is a novel long noncoding RNA. Increasing studies have reported that FAM83H-AS1 is abnormally expressed in a variety of tumors and is associated with poor outcome. However, the clinical prognostic significance of lncRNA FAM83H-AS1 in tumors is not completely known. Methods:In this meta-analysis, literature was collected up until February 5, 2020 through multifarious retrieval strategies by searching through electronic databases of PubMed, Cochrane Library, EMBASE, Medline, Web of Science, CNKI, Weipu, and Wanfang. A total of 14 studies that met the inclusion criteria with relevant clinical data and prognostic information were included in the meta-analysis. Results:The combined results revealed that high expression of FAM83H-AS1 was associated with poor overall survival (OS) (HR = 1.63, 95% CI 1.24-2.14, P = 0.0004) in a variety of cancers. Additionally, upregulated FAM83H-AS1 expression was significantly correlated with tumor TNM stage (III/IV vs. I/II, OR = 2.40, 95% CI 1.36-4.23, P = 0.003) and lymph node metastasis (positive vs. negative, OR = 1.70, 95% CI 1.14-2.52, P = 0.008) in patients with cancer. Conclusions:Our results of this meta-analysis indicated that elevated FAM83H-AS1 expression could predict poor prognosis in patients with cancer and suggested that FAM83H-AS1 might serve as a novel biomarker for cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Characteristics and Basic Information In Eligible Literaturementioning

confidence: 99%

See 1 more Smart Citation

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

Yang¹,

Wang²,

Zhong³

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Despite great efforts to use these advances in the clinic, only six of the lncRNAs listed in Table S1 have been identified in OC patients' blood serum samples; namely, E2F4AS [117], FEZF1-AS1 [20], FLVCR1-AS1 [41], LINK-A [26], MLK7-AS1 [40] and aHIF [13], the last-named being isolated specifically from exosomes in the serum. MEG3 and MALAT1 are probably on the way to being added to the list since they have been identified in exosomes derived from OC cell lines [26,107]. Interestingly, the serum and tumor tissue levels of aHIF, FEZF1-AS1, FLVCR1-AS1, LINK-A, and MLK7-AS1 correlate positively, providing a proof of concept for the usefulness of lncRNAs in liquid biopsy.…”

Section: Platinum Salts Taxanesmentioning

confidence: 99%

“…Surveying the function of lncRNAs globally (Figure 2b), 120 are considered as oncogenes, 114 confirmed and six putative; and 29 are considered as tumor suppressor genes, 25 confirmed and four putative. SPRY-IT1 [26], MEG3 [122,123], XIST [54,99] and TTN-AS1 [65,124] statuses remain unclear because the shreds of evidence collected are ambiguous. The experimental data about TC0101686, TC0100223, TC0901107, and TC1500845 show only that they are transcriptionally activated by estrogens.…”

Section: Lncrnas Implicated In Oc Development and Progressionmentioning

confidence: 99%

The Challenges and Opportunities of LncRNAs in Ovarian Cancer Research and Clinical Use

Salamini-Montemurri

Lamas-Maceiras

Barreiro-Alonso

et al. 2020

Cancers

View full text Add to dashboard Cite

Ovarian cancer is one of the most lethal gynecological malignancies worldwide because it tends to be detected late, when the disease has already spread, and prognosis is poor. In this review we aim to highlight the importance of long non-coding RNAs (lncRNAs) in diagnosis, prognosis and treatment choice, to make progress towards increasingly personalized medicine in this malignancy. We review the effects of lncRNAs associated with ovarian cancer in the context of cancer hallmarks. We also discuss the molecular mechanisms by which lncRNAs become involved in cellular physiology; the onset, development and progression of ovarian cancer; and lncRNAs' regulatory mechanisms at the transcriptional, post-transcriptional and post-translational stages of gene expression. Finally, we compile a series of online resources useful for the study of lncRNAs, especially in the context of ovarian cancer. Future work required in the field is also discussed along with some concluding remarks.

show abstract

Long non‐coding RNA FAM83H‐AS1 as an emerging marker for diagnosis, prognosis and therapeutic targeting of cancer

El-Ashmawy

Al-Ashmawy

Hamouda

2020

Cell Biochemistry & Function

View full text Add to dashboard Cite

Incidence and mortality rates of cancer continue to increase greatly despite the improved diagnostic and therapeutic methods. Based on GLOBOCAN estimates, the numbers of new cancer cases reported in 2018 were ~18.1 million, while the numbers of cancer mortalities were ~9.6 million. It remains difficult to diagnose most cancer patients at early stages. Although cancer therapy market is rapidly evolving, the effectiveness of therapy is still inadequate. Therefore, exploring new biomarkers for diagnosis, prognosis and treatment is essential for cancer management. Long non‐coding RNAs (lncRNAs) are unique regulatory molecules that control several cellular processes and are implicated in diverse human diseases including cancer. LncRNAs could serve as potential biomarkers for cancer patients to aid diagnosis and determine prognosis. In addition, numerous lncRNAs have proved their ability to predict response to cancer treatment. FAM83H antisense RNA 1 (FAM83H‐AS1) is among those highly dysregulated lncRNAs in cancer. FAM83H‐AS1 was demonstrated to participate in the progression of different malignancies and also shown to play a vital role in diagnosis, prognosis and treatment. Here, we analyse recent studies concerning the oncogenic role and molecular mechanisms of lncRNA FAM83H‐AS1 in the following cancer types: bladder, breast, lung, hepatocellular, colorectal, gastric, pancreatic, ovarian, cervical cancer as well as glioma.

show abstract

LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein

Cited by 48 publications

References 23 publications

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

The Challenges and Opportunities of LncRNAs in Ovarian Cancer Research and Clinical Use

Long non‐coding RNA FAM83H‐AS1 as an emerging marker for diagnosis, prognosis and therapeutic targeting of cancer

Contact Info

Product

Resources

About